Metabolife
This article was originally published in The Tan Sheet
Executive Summary
FDA should establish a "new working group composed of scientists, agency experts, consumers, herbalists and industry to design a better system for reporting suspected adverse health events" related to dietary and herbal supplement use, Metabolife International CEO Michael Ellis states in an Aug. 11 letter to Commissioner Jane Henney, MD. Metabolife markets the ephedra weight loss product Metabolife 356; the letter comes close on the heels of the GAO report concerning FDA's proposed rule restricting the use of ephedrine alkaloids in dietary supplements (1"The Tan Sheet" Aug. 9, pp. 3-5). FDA's AER system for dietary supplements also was the subject of a House Government Reform Committee hearing May 27 (2"The Tan Sheet" May 31, pp. 3-5)
You may also be interested in...
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.
FDA Supplement AE Monitoring System Has "Six Problem Areas" - Burton
"Six problem areas" exist in the FDA Center for Food Safety & Applied Nutrition adverse event monitoring system for dietary supplements that need to be resolved, House Government Reform Committee Chairman Dan Burton (R-Ind.) declared at a May 27 hearing.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC